Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder

CNS Spectr. 2021 Jun;26(3):185-187. doi: 10.1017/S1092852919001627. Epub 2019 Nov 21.

Authors

Jagannadha Avasarala¹, Brent S Sokola², Selina Mullins²

Affiliations

¹ Department of Neurology, Section of Multiple Sclerosis and Neuroimmunology, University of Kentucky Albert Chandler Medical Center, Lexington, Kentucky, USA.
² Specialty Pharmacy & Infusion Services, University of Kentucky, Lexington, Kentucky, USA.

PMID: 31747983
DOI: 10.1017/S1092852919001627

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Complement Inactivating Agents / administration & dosage
Complement Inactivating Agents / adverse effects*
Complement Inactivating Agents / therapeutic use
Drug Labeling / standards*
Humans
Meningitis, Meningococcal / epidemiology
Meningitis, Meningococcal / prevention & control
Meningococcal Vaccines / administration & dosage*
Neuromyelitis Optica / drug therapy*

Substances

Antibodies, Monoclonal, Humanized
Complement Inactivating Agents
Meningococcal Vaccines
eculizumab